Citations

Showing 10 of 108104 citations.

Molecular analysis of NUT‐positive poromas and porocarcinomas identifies novel break points of YAP1::NUTM1 fusions
Snow, Justin T., Georgantzoglou, Natalia , Green, Donald C., Parra, Ourania , LeBlanc, Robert E. , Yan, Shaofeng , Sriharan, Aravindhan, Momtahen, Shabnam , Winnick, Kimberley N., Dimonitsas, Emmanouil , Stavrianos, Spiros, Lakiotaki, Eleftheria , Revelos, Kyriakos , Guo, Ruifeng , Linos, Konstantinos , Linos, Konstantinos , Guo, Ruifeng , Stavrianos, S. , Korkolopoulou, Penelope A.

Mayo Clinic

Journal of Cutaneous Pathology | June 4, 2022 | Volume: 49 | Issue: 10 | Pages: 850-858

10.1111/cup.14265 | PMID 35665951 Get It

AbstractBackgroundPoromas, and their malignant counterparts, porocarcinomas, harbor recurrent translocations involving YAP1‐MAML2, YAP1‐NUTM1, and infrequently WWTR1‐NUTM1; YAP1‐NUTM1 being the most common in porocarcinomas. NUT immunohistochemistry (IHC) can be used to identify NUTM1‐translocated tumors. This study sought to investigate potential novel NUTM1‐fusion partners among NUT IHC‐positive poromas and porocarcinomas.MethodsThirteen NUT IHC‐positive poroid tumors (four poromas and nine porocarcinomas) were identified within a multi‐institutional international cohort. Next‐generation sequencing (NGS) assessed for NUTM1 fusion partners.ResultsNGS detected a NUTM1 fusion in 12 of 13 cases: YAP1‐NUTM1 (11/12 cases) and WWTR1‐NUTM1 (1/12 cases). Two of the cases (2/12) with NUTM1 fusion were not called by the NGS algorithm but had at least one read‐spanning YAP1‐NUTM1 break point upon manual review. A NUTM1 fusion was not identified in one case; however, the sample had low RNA quality. The following fusion events were identified: YAP1 exon 4::NUTM1 exon 3 in six cases, YAP1 exon 6::NUTM1 exon 2 in one case, YAP1 exon 3::NUTM1 exon 3 in three cases, WWTR1 exon 3::NUTM1 exon 3 in one case, and YAP1 exon 8::NUTM1 exon 3 fusion in one case.ConclusionWhile no novel NUTM1 fusion partners were identified within our cohort, 12 of 13 cases had discoverable NUTM1 fusions; YAP1‐NUTM1 fusion was detected in 11 cases (92%) and WWTR1‐NUTM1 in 1 case (8%). These data corroborate findings from other recent investigations and further substantiate the utility of NUT IHC in diagnosing a subset of poroid neoplasms. In addition, two of our cases harbored fusions of YAP1 exon 6 to NUTM1 exon 3 and YAP1 exon 8 to NUTM1 exon 2, which have not been reported before in poroid neoplasms and indicate novel break points of YAP1.
Process mapping strategies to prevent subcutaneous implantable cardioverter‐defibrillator infections
Weiss, Raul , Mark, George E., Lambiase, Pier D. , Miller, Marc A. , McClernon, Timothy R., Knight, Bradley P. , El-Chami, Mikhael F , Miller, Marc A , Lambiase, Pier D , Knight, Bradley P , Weiss, Raul , El‐Chami, Mikhael F. , Biffi, Mauro , Probst, Vincent , Hansen, Linda K. , Baddour, Larry M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 4, 2022 | Volume: 33 | Issue: 7 | Pages: 1628-1635

10.1111/jce.15566 | PMID 35662315 Get It

AbstractBackgroundInfection remains a major complication of cardiac implantable electronic devices and can lead to significant morbidity and mortality. Implantable devices that avoid transvenous leads, such as the subcutaneous implantable cardioverter‐defibrillator (S‐ICD), can reduce the risk of serious infection‐related complications, such as bloodstream infection and infective endocarditis. While the 2017 AHA/ACC/HRS guidelines include recommendations for S‐ICD use for patients at high risk of infection, currently, there are no clinical trial data that address best practices for the prevention of S‐ICD infections. Therefore, an expert panel was convened to develop a consensus on these topics.MethodsAn expert process mapping methodology was used to achieve consensus on the appropriate steps to minimize or prevent S‐ICD infections. Two face‐to‐face meetings of high‐volume S‐ICD implanters and an infectious diseases specialist, with expertise in cardiovascular implantable electronic device infections, were conducted to develop consensus on useful strategies pre‐, peri‐, and postimplant to reduce S‐ICD infection risk.ResultsExpert panel consensus on recommended steps for patient preparation, S‐ICD implantation, and postoperative management was developed to provide guidance in individual patient management.ConclusionAchieving expert panel consensus by process mapping methodology for S‐ICD infection prevention was attainable, and the results should be helpful to clinicians in adopting interventions to minimize risks of S‐ICD infection.
Online geriatric education for health professions students
Gleason, Lauren J. , Leipzig, Rosanne M. , Ramaswamy, Ravishankar , Ramaswamy, Ravishankar , Shah, Amit

Mayo Clinic

Journal of the American Geriatrics Society | June 4, 2022 | Volume: 70 | Issue: 9 | Pages: 2725-2727

10.1111/jgs.17915 | PMID 35665916 Get It

Dravet Syndrome as an Example of Precision Medicine in Epilepsy
Sullivan, Joseph , Wirrell, Elaine

Mayo Clinic

Epilepsy Currents | June 4, 2022 | Volume: 23 | Issue: 1 | Pages: 4-7

10.1177/15357597221106281 | PMID 36923331 Get It

Dravet syndrome (DS) is a drug-resistant, early-onset, developmental and epileptic encephalopathy where there have been many recently approved therapies with many more in development. With the availability of more syndrome specific treatment options coupled with an earlier diagnosis, DS is well-positioned to be an example of how a precise syndromic diagnosis can guide treatment choices and improve overall outcomes and also allow for the development of potential disease modifying therapies to address more than just seizures. In this review we summarize the current state of DS approved therapies and those that are in various stages of development.
Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: Results from a systematic review and meta-analysis
Waqar, Mueez , Roncaroli, Federico , Lehrer, Eric J. , D’Urso, Pietro Ivo , Quiñones‐Hinojosa, Alfredo , Trifiletti, Daniel M , Roncaroli, F , Palmer, Joshua D. , Villanueva-Meyer, Javier E. , Braunstein, Steve , Hall, Emma , Aznar, Marianne Camille , Hamer, Philip C. De Witt , Trifiletti, Daniel M. , Wesseling, Pieter , Borst, Gerben R.

Mayo Clinic

Neuro-Oncology Advances | June 4, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac075 | PMID 35769410 Get It

Abstract Background In patients with newly diagnosed glioblastoma, rapid early progression (REP) refers to tumor regrowth between surgery and postoperative chemoradiotherapy. This systematic review and meta-analysis appraised previously published data on REP to better characterize and understand it. Methods Systematic searches of MEDLINE, EMBASE and the Cochrane database from inception to October 21, 2021. Studies describing the incidence of REP—tumor growth between the postoperative MRI scan and pre-radiotherapy MRI scan in newly diagnosed glioblastoma were included. The primary outcome was REP incidence. Results From 1590 search results, 9 studies were included with 716 patients. The median age was 56.9 years (IQR 54.0–58.8 y). There was a male predominance with a median male-to-female ratio of 1.4 (IQR 1.1–1.5). The median number of days between MRI scans was 34 days (IQR 18–45 days). The mean incidence rate of REP was 45.9% (range 19.3%–72.0%) and significantly lower in studies employing functional imaging to define REP (P < .001). REP/non-REP groups were comparable with respect to age (P = .99), gender (P = .33) and time between scans (P = .81). REP was associated with shortened overall survival (HR 1.78, 95% CI 1.30–2.43, P < .001), shortened progression-free survival (HR 1.78, 95% CI 1.30–2.43, P < .001), subtotal resection (OR 6.96, 95% CI 4.51–10.73, P < .001) and IDH wild-type versus mutant tumors (OR 0.20, 95% CI 0.02–0.38, P = .03). MGMT promoter methylation was not associated with REP (OR 1.29, 95% CI 0.72–2.28, P = .39). Conclusions REP occurs in almost half of patients with newly diagnosed glioblastoma and has a strongly negative prognostic effect. Future studies should investigate its biology and effective treatment strategies.
Endoscopic Endonasal Approach to the Third Ventricle Using the Surgical Corridor of the Reverse Third Ventriculostomy: Anatomo-Surgical Nuances
Karadağ, Ali , Çamlar, Mahmut , Turkis, Omer Furkan , Bayramlı, Nijat, Middlebrooks, Erik H. , Middlebrooks, Erik H , Tanriover, Necmettin

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0042-1748630 Get It

Abstract Objective Surgical access to the third ventricle can be achieved through various corridors depending on the location and extent of the lesion; however, traditional transcranial approaches risk damage to multiple critical neural structures. Methods Endonasal approach similar to corridor of the reverse third ventriculostomy (ERTV) was surgically simulated in eight cadaveric heads. Fiber dissections were additionally performed within the third ventricle along the endoscopic route. Additionally, we present a case of ERTV in a patient with craniopharyngioma extending into the third ventricle. Results The ERTV allowed adequate intraventricular visualization along the third ventricle. The extracranial step of the surgical corridor included a bony window in the sellar floor, tuberculum sella, and the lower part of the planum sphenoidale. ERTV provided an intraventricular surgical field along the foramen of Monro to expose an area bordered by the fornix anteriorly, thalamus laterally, anterior commissure anterior superiorly, posterior commissure, habenula and pineal gland posteriorly, and aqueduct of Sylvius centered posterior inferiorly. Conclusion The third ventricle can safely be accessed through ERTV either above or below the pituitary gland. ERTV provides a wide exposure of the third ventricle through the tuber cinereum and offers access to the anterior part as far as the anterior commissure and precommissural part of fornix and the whole length of the posterior part. Endoscopic ERTV may be a suitable alternative to transcranial approaches to access the third ventricle in selected patients.
Blood Pressure Variability After Cerebrovascular Events: A Possible New Therapeutic Target
Hawkes, Maximiliano A. , Anderson, Craig S. , Rabinstein, Alejandro A.

Mayo Clinic

Neurology | June 3, 2022 | Volume: 99 | Issue: 4 | Pages: 150-160

10.1212/wnl.0000000000200856 | PMID 35879090 Get It

Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020
Stevens, Maria , Tsai, Jennifer , Nath, Bidisha , Melnick, Edward R. , D’Onofrio, Gail , Jeffery, Molly M. , Stevens, Maria A, Savitz, Samuel T. , Jeffery, Molly Moore , Melnick, Edward R

Mayo Clinic

JAMA Network Open | June 3, 2022 | Volume: 5 | Issue: 6 | Pages: e2215287

10.1001/jamanetworkopen.2022.15287 | PMID 35657629 Get It

Multi‐disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post‐acute sequelae of SARS‐CoV‐2 infection (PASC)
Barry, John T., Bartels, Matthew N. , Fleming, Talya K. , McCauley, Mark , Neal, Jacqueline D., Pillarisetti, Jayasree , Sampsel, Sarah , Terzic, Carmen M., Tosto, Jenna, Fleming, Talya K , Sampsel, Sarah , Verduzco-Gutierrez, Monica , Whiteson, Jonathan H. , Azola, Alba Miranda , Blitshteyn, Svetlana , Silver, Julie K. , Verduzco‐Gutierrez, Monica , Putrino, David F.

Mayo Clinic

PM&R | June 3, 2022 | Volume: 14 | Issue: 7 | Pages: 855-878

10.1002/pmrj.12859 | PMID 35657351 Get It